Cart
sales@molnova.com
ILK-IN-3
CAS No. 6975-75-3
ILK-IN-3( —— )
Catalog No. M22072 CAS No. 6975-75-3
ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 101 | In Stock |
|
| 25MG | 202 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 449 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameILK-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
-
DescriptionILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.(In Vitro):ILK-IN-3 (compound 4, 10 μM) inhibits DYRK1, GSK3α/β, CDK5/p25 kinase activity to 17%, 51%, 47%, 95%, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6975-75-3
-
Formula Weight232.24
-
Molecular FormulaC10H12N6O?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (358.81 mM)
-
SMILESCOC1=CC=C(C=C1)N=NC2=C(NN=C2N)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38.
molnova catalog
related products
-
OSU-T315
A novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM.
-
RBC8
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
